Zentalis Pharmaceuticals

Edit info

Founded: 2017

Location: San Diego, CA

Employee range: 50 - 200

Clinical stage: Clin2 (fast track)

Therapy area: Uterine cancer

Drug types: ONC, RAR

Lead product: ZN-c3 (partners: Pfizer, GSK, Zentera)

Funding: $250M stock Jun 2023; $190M IPO Apr 2020; $85M C Dec 2019 ($147 total Dec 2019)

zentalis.com

linkedin.com

job board

Drug notes:

Also 5 additional trials Clin1/Clin2 multiple cancers; ZN-c5 Clin2 (development to be discontinued after trial) breast cancer (partner Zentera); Zn-d5 (partner: Zentera) Clin1 AL amyloidosis, Clin1 AML, NHL, combo Clin0 AML; Zn-e4 (partner: SciClone Pharmaceuticals) Clin1 (development to be discontinued after trial) NSCLC; undisclosed Clin0 multiple cancers

About:

Zentalis Pharmaceuticals is developing small molecule therapeutics targeting fundamental biological pathways of cancers. The company's unique science is based on its proprietary Integrated Discovery Engine (IDE), which combines expertise in medicinal chemistry, computational biology, and translational oncology to identify and develop novel drug candidates. Zentalis' IDE has the potential to accelerate the drug discovery process and identify more effective and less toxic drug candidates than traditional approaches. The company's lead product candidate, azenosertib, is a Wee1 inhibitor that is currently in Phase 3 clinical trials for the treatment of ovarian cancer.